GLP-1/GIP Dual Agonist

1 compound in this category.

Tirzepatide

FDA Approved

Mounjaro, Zepbound

A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies…

Route

SubQ (Mounjaro/Zepbound)

Dose

2.5 mg → 15 mg (titrated over 20 weeks)

Cycle

Ongoing — not typically cycled

Weight managementType 2 diabetes treatmentMetabolic health improvement

All Categories

Anti-Aging & Longevity (2)Anti-Aging & Skin (2)Anti-Inflammatory & Healing (1)Anticoagulant (1)Antioxidant & Detox (1)Bone & Metabolic (3)Cosmetic & Skin (4)GLP-1 Agonist (6)GLP-1/GIP Dual Agonist (1)GLP-1/GIP/Glucagon Triple Agonist (1)GnRH Agonist (1)Growth & Anabolic (2)Growth & Recovery (2)Growth Hormone Secretagogue (7)Healing & Recovery (6)Hormonal & Renal (1)Hormonal & Reproductive (3)Immune & Antimicrobial (3)Immune & Longevity (1)Immune & Neurological (1)Immune & Respiratory (1)Immune Support (2)Melanocortin & Sexual Health (2)Metabolic (5)Metabolic & Longevity (2)Metabolic & Weight Management (5)Mitochondrial & Cardioprotective (1)Mitochondrial & Longevity (1)Neurological & Hormonal (1)Nootropic & Cognitive (1)Nootropic & Neuroprotective (5)Sleep & Neurological (1)Sleep & Recovery (1)Somatostatin Analog (2)Structural & Skin (1)